MORBO DI CROHN: INIBITORI DELLA IL-23p19 vs IL-12/23p40. UNA MAGNIFICA REVISIONE SISTEMATICA CON NETWORK META-ANALISI. DA “ANNALS OF MEDICINE” (FREE!)
Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis Motoki Kaneko, Atsushi Sakuraba Abstract Background Interleukin (IL)-23 inhibitors—including IL-23p19 inhibitors (guselkumab, mirikizumab, risankizumab) and the IL-12/23p40 inhibitor ustekinumab—are emerging treatments for Crohn’s disease (CD), but comparative data among them remain limited. Most previous network meta-analyses (NMAs) compared IL-23…
